Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer Research

• Publication date

  2009-03-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-08-1056PMID 19276389
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression of Epidermal Growth Factor Receptor or ErbB3 Facilitates Geldanamycin-Induced Down-Regulation of ErbB2

  2009cited by this paper
• HER2 status and benefit from adjuvant trastuzumab in breast cancer.

  2008cited by this paper
• 17β-Estradiol Promotes Breast Cancer Cell Proliferation-Inducing Stromal Cell-Derived Factor-1-Mediated Epidermal Growth Factor Receptor Transactivation: Reversal by Gefitinib Pretreatment

  2008cited by this paper
• Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability

  2008cited by this paper
• HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer

  2008cited by this paper
• Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.

  2008cited by this paper
• Expression of t-DARPP Mediates Trastuzumab Resistance in Breast Cancer Cells

  2008cited by this paper
• Part II: management of resistance to imatinib in chronic myeloid leukaemia.

  2007cited by this paper
• Trastuzumab: triumphs and tribulations

  2007cited by this paper
• Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.

  2007cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2007cited by this paper
• Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network

  2007cited by this paper
• Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer

  2007cited by this paper
• Genetic screening for signal transduction in the era of network biology.

  2007cited by this paper
• Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy

  2007cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cited by this paper
• Cancer biology: Signatures guide drug choice

  2006cited by this paper
• Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

  2006cited by this paper
• Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

  2005cited by this paper
• Anti‐HER‐3 MAbs inhibit HER‐3‐mediated signaling in breast cancer cell lines resistant to anti‐HER‐2 antibodies

  2005cited by this paper
• PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

  2004cited by this paper
• Epidermal growth factor receptor dependence in human tumors: more than just expression?

  2002cited by this paper
• A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.

  2001cited by this paper
• Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.

  2001cited by this paper

• The Impact of HER3 Dynamics Altered by HER3-DXd Alone and in Combination with Driver Oncogene Inhibitors on HER3-DXd Efficacy.

  2026cites this paper
• Mechanisms of resistance to antibody-drug conjugates in cancer: molecular barriers and pharmacological solutions

  2025cites this paper
• Design, Synthesis and Molecular Docking of New Thieno[2,3‑d]Pyrimidin‐4‐One Derivatives as Dual EGFR and FGFR Inhibitors

  2025cites this paper
• Dual targeted lipid nanoparticles for enhanced DNA delivery and transfection of breast cancer cells.

  2025cites this paper
• Multiparametric Analysis of PET and Quantitative MRI for Identifying Intratumoral Habitats and Characterizing Trastuzumab-Induced Alterations

  2025cites this paper
• HER3 upregulation reduces DS-8201 sensitivity in HER2-positive tumor cells by ATR/CHK1/FoxO1 signaling cascade

  2025cites this paper
• Targeting PGK1 as a Novel strategy to regulate the sensitivity of HER2 positive gastric cancer to lapatinib

  2025cites this paper
• Dual Role of Diallyl Disulfide (DADS) on Invasive Potential and β-Catenin Dynamics in HER2-Positive Breast Cancer Cells

  2025cites this paper
• Overcoming retinoic acid resistance in HER2‐enriched breast cancers: role of MYC

  2024cites this paper
• Resistance to antibody–drug conjugates: A review

  2024cites this paper
• Mechanisms of Acquired Resistance to HER2-Positive Breast Cancer Therapies Induced by HER3: A Comprehensive Review.

  2024cites this paper
• Multiparametric profiling of HER2-enriched extracellular vesicles in breast cancer using Single Extracellular VEsicle Nanoscopy

  2024cites this paper
• Evolving Management of Breast Cancer in the Era of Predictive Biomarkers and Precision Medicine

  2024cites this paper
• Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy.

  2024cites this paper
• Adenovirus-Derived Nano-Capsid Platforms for Targeted Delivery and Penetration of Macromolecules into Resistant and Metastatic Tumors

  2023cites this paper
• Lipid Metabolism Reprogramming and Trastuzumab Resistance in Breast Cancer Cell Lines Overexpressing the ERBB2 Membrane Receptor

  2023cites this paper
• PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications

  2023cites this paper
• Development of a bispecific DNA-aptamer-based lysosome-targeting chimera for HER2 protein degradation

  2023cites this paper
• HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer

  2023cites this paper
• Emerging insights into mechanisms of trastuzumab resistance in HER2-positive cancers.

  2023cites this paper
• Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2‐positive gastric cancer

  2023cites this paper
• HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma

  2023cites this paper
• Anti-HER2 therapy in metastatic breast cancer: many choices and future directions

  2022cites this paper
• Landscape of Epidermal Growth Factor Receptor Heterodimers in Brain Metastases

  2022cites this paper
• Overcoming Resistance to HER2-Directed Therapies in Breast Cancer

  2022cites this paper
• HER3 in cancer: from the bench to the bedside

  2022cites this paper
• Translational aspects of biologicals: monoclonal antibodies and antibody-drug conjugates as examples

  2021cites this paper
• Regulation on tumor metastasis by Raf kinase inhibitory protein: New insight with reactive oxygen species signaling

  2021cites this paper
• Systemic ligand-mimicking bioparticles cross the blood-brain barrier and reduce growth of intracranial triple-negative breast cancer using the human epidermal growth factor receptor 3 (HER3) to mediate both routes

  2021cites this paper
• Microwave-Assisted Chitosan-Functionalized Graphene Oxide as Controlled Intracellular Drug Delivery Nanosystem for Synergistic Antitumour Activity

  2021cites this paper
• New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.

  2021cites this paper
• Long Non-coding RNA Small Nucleolar RNA Host Gene 14, a Promising Biomarker and Therapeutic Target in Malignancy

  2021cites this paper
• Human Epidermal Growth Factor Receptor-3 Expression Is Regulated at Transcriptional Level in Breast Cancer Settings by Junctional Adhesion Molecule-A via a Pathway Involving Beta-Catenin and FOXA1

  2021cites this paper
• Bispecific Antibody Molecule Inhibits Tumor Cell Proliferation More Efficiently Than the Two-Molecule Combination

  2021cites this paper
• HER2 Signaling in Breast Cancer.

  2021cites this paper
• MALAT1 Promotes Tumorigenesis and Increases Cellular Sensitivity to Herceptin in HER2-positive Breast Cancer.

  2021cites this paper
• 89Zr-Labeled Domain II-Specific scFv-Fc ImmunoPET Probe for Imaging Epidermal Growth Factor Receptor In Vivo

  2021cites this paper
• Role of Her-2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine

  2020cites this paper
• Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor

  2020cites this paper
• Anticancer therapeutics: a brief account on wide refinements.

  2020cites this paper
• HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials

  2020cites this paper
• Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors.

  2020cites this paper
• HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

  2020cites this paper
• Synthesis and validation of [18F]mBPET-1, a fluorine-18 labelled mTOR inhibitor derivative based on a benzofuran backbone

  2020cites this paper
• LncRNA IGBP1-AS1/miR-24-1/ZIC3 loop regulates the proliferation and invasion ability in breast cancer

  2020cites this paper
• Modelling the role of dual specificity phosphatases in Herceptin resistant breast cancer cell lines

  2019cites this paper
• Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers

  2019cites this paper
• Long Non-Coding RNA in the Pathogenesis of Cancers

  2019cites this paper
• HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer

  2019cites this paper
• ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics

  2019cites this paper
• Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer

  2019cites this paper
• Current Updates on Trastuzumab Resistance in HER2 Overexpressing Breast Cancers.

  2019cites this paper
• The Role of miRNAs from the 14q32 Region in Acquired Resistance to Lapatinib

  2019cites this paper
• Systems Biology in Biomarker Development for Cancer Signaling Therapy

  2019cites this paper
• Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer

  2019cites this paper
• A Novel HER3-Targeting Antibody–Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization

  2019cites this paper
• HER3-targeted protein chimera forms endosomolytic capsomeres and self-assembles into stealth nucleocapsids for systemic tumor homing of RNA interference in vivo

  2019cites this paper
• Trastuzumab in combination with AT-101 induces cytotoxicity and apoptosis in Her2 positive breast cancer cells.

  2019cites this paper
• Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4–1 and NRDP1, in primary breast cancer

  2018cites this paper
• Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs.

  2018cites this paper
• Long non‐coding RNA SNHG14 induces trastuzumab resistance of breast cancer via regulating PABPC1 expression through H3K27 acetylation

  2018cites this paper
• Anti-neoplastic cytotoxicity by complementary simultaneous selective “targeted” delivery for pulmonary adenocarcinoma: fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] in dual-combination with dexamethasone-(C21-phosphoramidate)-[anti-EGFR]

  2018cites this paper
• Exosome-mediated transfer of lncRNA-SNHG14 promotes trastuzumab chemoresistance in breast cancer

  2018cites this paper
• Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies.

  2018cites this paper
• SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88

  2018cites this paper
• aptamer sirna technology provides a simple platform for cancer combination treatment

  2018cites this paper
• Dual silencing of EGFR and HER2 enhances the sensitivity of gastric cancer cells to gefitinib

  2018cites this paper
• HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging

  2018cites this paper
• Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1

  2018cites this paper
• Site-Specific Fluorescent Labeling of Antibodies and Diabodies Using SpyTag/SpyCatcher System for In Vivo Optical Imaging

  2018cites this paper
• Breast Cancer Cell Apoptosis is Synergistically Induced by Curcumin, Trastuzumab, and Glutathione Peroxidase-1 but Robustly Inhibited by Glial Cell Line-Derived Neurotrophic Factor

  2018cites this paper
• Anti-neoplastic cytotoxicity by complementary simultaneous selective “targeted” delivery for pulmonary adenocarcinoma: fludarabine-(5′-phosphoramidate)-[anti-IGF-1R] in dual-combination with dexamethasone-(C21-phosphoramidate)-[anti-EGFR]

  2018cites this paper
• Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade.

  2018cites this paper
• Clinical development of HER3-targeting monoclonal antibodies: Perils and progress.

  2018cites this paper
• Mechanisms of Action and Resistance of Trastuzumab in Breast Cancer

  2018cites this paper
• Carnosic acid, Tangeretin, and Ginkgolide-B Anti-Neoplastic Cytotoxicity in Dual Combination with Dexamethasone-[anti-EGFR] in Pulmonary Adenocarcinoma (A549).

  2018cites this paper
• Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance

  2018cites this paper
• Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer

  2017cites this paper
• Untangling The Gene-Epigenome Networks: Timing Of Epigenetic Regulation Of Gene Expression In Acquired Cetuximab Resistance

  2017cites this paper
• Uncivering mechanisms of acquired resistance to trastuzumab-emtansine (T-DM1) in HER2 positive breast cancer

  2017cites this paper
• An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression

  2017cites this paper
• Cell line and protein engineering tools for production and characterization of biologics

  2017cites this paper
• NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.

  2017cites this paper
• Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer

  2017influential citation
• FEN1 knockdown improves trastuzumab sensitivity in human epidermal growth factor 2-positive breast cancer cells.

  2017cites this paper
• Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis

  2017cites this paper
• Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer.

  2017cites this paper
• Integrating imaging, exosome and protein network rewiring information to track early tumour evolution of resistance mechanisms

  2017cites this paper
• siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells

  2017cites this paper
• Aberrant intracellular metabolism of T‐DM1 confers T‐DM1 resistance in human epidermal growth factor receptor 2‐positive gastric cancer cells

  2017cites this paper
• A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells

  2017cites this paper
• Resistance to HER2-Targeted Therapy

  2017cites this paper
• Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics

  2017cites this paper
• Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance

  2017cites this paper
• Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)

  2016cites this paper
• Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer

  2016cites this paper
• ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation

  2016cites this paper
• Gemcitabine‐(5′‐phosphoramidate)‐[anti‐IGF‐1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549)

  2016cites this paper
• Disease-associated glycans on cell surface proteins.

  2016cites this paper
• ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3

  2016cites this paper